Upload
lucas-cruz
View
2.596
Download
1
Embed Size (px)
DESCRIPTION
Presentation about monobactams antibiotics
Citation preview
MonobactamsLucas Cruz, Brasil
Chromobacterium violaceum
Enzymatic
inactivation
Antibiotic efflux
Modification of the
target receptor
Difficulty of
penetrating the
cell
Resistance
Spectrum of Action:
Aerobic Gram-negatives
IV ou IM
Pharmacokinetics
Drug Interactions
Clinical use
Urinary Tract Infection
Gram-negative sepsis
Cystic
Fibrosis
1 g, 8/8 or 12/12H
Via IV
500mg, 12H
2g, de 6/6h
30mg/kg 12, 8 our6/6h
Dose
Side effects
Comercial presentation
1. Aztreonam acts only against gram-negative aerobiic
2.Is resistant to beta-lactamases
3. Few side effects
4. It is useful in the treatment of patients allergic to penicillin
Don’t
forget:
Bibliografic References:
• TAVARES, W. Antibióticos e quimioterápicos para o clínico/Walter Tavares. 2ª ed. Ver. e atual. São Paulo: Editora Atheneu, 2009. p. 210 a 212.
• VINKS, A. A.. et al. Pharmacokinetics of Aztreonam in Healthy Subjects and Patients with Cystic Fibrosis and Evaluation of Dose-Exposure Relationships Using Monte Carlo Simulation. 2007. American Society for microbiology. Disponível em:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2043218/?tool=pubmed/ Acessado em: 04 de dezembro de 2010.
• WALKININE, Y. FDA Approves Inhaled Aztreonam for Cystic Fibrosis. 2010. MedScape. Disponível em: http://www.medscape.com/viewarticle/717553 Acessado em: 05 de dezembro de 2010.